摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-Bromophenoxy)-N-[4-(5-methylthiophen-2-YL)-13-thiazol-2-YL]acetamide

中文名称
——
中文别名
——
英文名称
2-(4-Bromophenoxy)-N-[4-(5-methylthiophen-2-YL)-13-thiazol-2-YL]acetamide
英文别名
2-(4-bromophenoxy)-N-[4-(5-methylthiophen-2-yl)-1,3-thiazol-2-yl]acetamide
2-(4-Bromophenoxy)-N-[4-(5-methylthiophen-2-YL)-13-thiazol-2-YL]acetamide化学式
CAS
——
化学式
C16H13BrN2O2S2
mdl
MFCD02244475
分子量
409.3
InChiKey
XGYNQUVWJBRDCU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    23
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    108
  • 氢给体数:
    1
  • 氢受体数:
    5

文献信息

  • AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY
    申请人:Shionogi & Co., Ltd.
    公开号:US20150038483A1
    公开(公告)日:2015-02-05
    The present invention is related to a compound represented by formula (I) wherein R 1 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclyl, or the like; X is —N(R 3 )—, —O—, or —S—; Y is ═C(R 4 )—, or ═N—; Z is —N(R 7 )—, —O—, or —S—; R 2 is substituted or unsubstituted alkyloxy, or the like, or a group represented by the following formula: —(CR 2a R 2b ) n —R 2c , wherein R 2a is each independently a hydrogen atom, halogen, or the like; R 2b is each independently a hydrogen atom, halogen, or the like; R 2a and R 2b which are attached to the same carbon atom may be taken together to form oxo, a substituted or unsubstituted non-aromatic carbocycle, or the like; two of R 2a which are attached to the adjacent carbon atoms and/or two of R 2b which are attached to the adjacent carbon atoms may be taken together to form a bond; R 2c is substituted or unsubstituted aromatic carbocyclyl, or the like; n is an integer from 1 to 3; R 3 and R 7 are each independently a hydrogen atom, substituted or unsubstituted alkyl, or the like; R 4 and R 5 are each independently a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like; R 6 is a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.
    本发明涉及一种由式(I)表示的化合物,其中R1是氢原子,取代或未取代的烷基,取代或未取代的芳香环烷基等;X是—N(R3)—,—O—或—S—;Y是═C(R4)—或═N—;Z是—N(R7)—,—O—或—S—;R2是取代或未取代的烷氧基等,或以下式表示的基团:—(CR2aR2b)n—R2c,其中R2a分别是氢原子,卤素等;R2b分别是氢原子,卤素等;附在同一碳原子上的R2a和R2b可以共同形成氧化物,取代或未取代的非芳香环烷基等;附在相邻碳原子上的两个R2a和/或附在相邻碳原子上的两个R2b可以共同形成键;R2c是取代或未取代的芳香环烷基等;n是1到3的整数;R3和R7分别是氢原子,取代或未取代的烷基等;R4和R5分别是氢原子,卤素,取代或未取代的烷基等;R6是氢原子,卤素,取代或未取代的烷基等,或其药学上可接受的盐,或包含其的药物组合物。
  • AROMATIC HETEROCYCLIC FIVE-MEMBERED RING DERIVATIVE HAVING TRPV4 INHIBITORY ACTIVITY
    申请人:Shionogi & Co., Ltd.
    公开号:EP2832731A1
    公开(公告)日:2015-02-04
    The present invention is related to a compound represented by formula (I) wherein R1 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclyl, or the like; X is -N(R3)-, -O-, or -S-; Y is =C(R4)-, or =N-; Z is -N(R7)-, -O-, or -S-; R2 is substituted or unsubstituted alkyloxy, or the like, or a group represented by the following formula: -(CR2aR2b)n-R2c, wherein R2a is each independently a hydrogen atom, halogen, or the like; R2b is each independently a hydrogen atom, halogen, or the like; R2a and R2b which are attached to the same carbon atom may be taken together to form oxo, a substituted or unsubstituted non-aromatic carbocycle, or the like; two of R2a which are attached to the adjacent carbon atoms and/or two of R2b which are attached to the adjacent carbon atoms may be taken together to form a bond; R2c is substituted or unsubstituted aromatic carbocyclyl, or the like; n is an integer from 1 to 3; R3 and R7 are each independently a hydrogen atom, substituted or unsubstituted alkyl, or the like; R4 and R5 are each independently a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like; R6 is a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.
    本发明涉及一种由式(I)表示的化合物 其中 R1 是氢原子、取代或未取代的烷基、取代或未取代的芳香族羰基或类似物;X 是-N(R3)-、-O-或-S-;Y 是=C(R4)-、或=N-;Z 是-N(R7)-、-O-或-S-; R2 是取代或未取代的烷氧基,或类似物,或下式所代表的基团:-(CR2aR2b)n-R2c,其中 R2a 各自独立地为氢原子、卤素或类似物;R2b 各自独立地为氢原子、卤素或类似物;连接到相同碳原子上的 R2a 和 R2b 可一起形成氧代、取代或未取代的非芳香族碳环或类似物;与相邻碳原子相连的两个 R2a 和/或与相邻碳原子相连的两个 R2b 可结合在一起形成键; R2c 是取代或未取代的芳香族碳环或类似物; n 是 1 到 3 的整数; R3 和 R7 各自独立地为氢原子、取代或未取代的烷基或类似物; R4 和 R5 各自独立地为氢原子、卤素、取代或未取代的烷基或类似物; R6 是氢原子、卤素、取代或未取代的烷基或类似物、 或其药学上可接受的盐,或由其组成的药物组合物。
  • US9499533B2
    申请人:——
    公开号:US9499533B2
    公开(公告)日:2016-11-22
查看更多

同类化合物

(R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (+)-6,6'-{[(1R,3R)-1,3-二甲基-1,3基]双(氧)}双[4,8-双(叔丁基)-2,10-二甲氧基-丙二醇 麦角甾烷-6-酮,2,3,22,23-四羟基-,(2a,3a,5a,22S,23S)- 鲁前列醇 顺式6-(对甲氧基苯基)-5-己烯酸 顺式-铂戊脒碘化物 顺式-四氢-2-苯氧基-N,N,N-三甲基-2H-吡喃-3-铵碘化物 顺式-4-甲氧基苯基1-丙烯基醚 顺式-2,4,5-三甲氧基-1-丙烯基苯 顺式-1,3-二甲基-4-苯基-2-氮杂环丁酮 非那西丁杂质7 非那西丁杂质3 非那西丁杂质22 非那西丁杂质18 非那卡因 非布司他杂质37 非布司他杂质30 非布丙醇 雷诺嗪 阿达洛尔 阿达洛尔 阿莫噁酮 阿莫兰特 阿维西利 阿索卡诺 阿米维林 阿立酮 阿曲汀中间体3 阿普洛尔 阿普斯特杂质67 阿普斯特中间体 阿普斯特中间体 阿托西汀EP杂质A 阿托莫西汀杂质24 阿托莫西汀杂质10 阿托莫西汀EP杂质C 阿尼扎芬 阿利克仑中间体3 间苯胺氢氟乙酰氯 间苯二酚二缩水甘油醚 间苯二酚二异丙醇醚 间苯二酚二(2-羟乙基)醚 间苄氧基苯乙醇 间甲苯氧基乙酸肼 间甲苯氧基乙腈 间甲苯异氰酸酯